{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:09:21Z","timestamp":1790633361721,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijid.2021.03.018","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:19:48Z","timestamp":1616073588000},"page":"298-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Dolutegravir response in antiretroviral therapy na\u00efve and experienced patients with M184V\/I: Impact in low-and middle-income settings"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-9402","authenticated-orcid":false,"given":"Emmanuel","family":"Ndashimye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4880-7968","authenticated-orcid":false,"given":"Eric J.","family":"Arts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.03.018_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0010","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/00002030-200208160-00017","article-title":"M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine","volume":"16","author":"Ait-Khaled","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.018_bib0015","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jac\/dkx042","article-title":"Prevalence of HIV-1 drug resistance in treated patients with viral load .50 copies\/mL: a 2014 French nationwide study","volume":"72","author":"Assoumou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0020","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkz009","article-title":"Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice","volume":"74","author":"Baldin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0025","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0030","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkw147","article-title":"Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine\/dolutegravir dual therapy","volume":"71","author":"Borghetti","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3666-8","article-title":"Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice","volume":"19","author":"Borghetti","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0040","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.37.10.2231","article-title":"High-level resistance to (-) enantiomeric 2\u2019-deoxy-3\u2019-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Boucher","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.03.018_bib0050","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.03.018_bib0055","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijid.2021.03.018_bib0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2755-4","article-title":"A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48weeks\u2019 observational data","volume":"17","author":"Capetti","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3851\/IMP3275","article-title":"Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients","volume":"24","author":"Ferrari","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2021.03.018_bib0080","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/JVI.74.14.6262-6268.2000","article-title":"Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection","volume":"74","author":"Frost","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2021.03.018_bib0085","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0090","doi-asserted-by":"crossref","first-page":"105893","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcomes of two-drugs regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically suppressed, HIV-infected patients","author":"Galizzi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2021.03.018_bib0095","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1128\/JVI.74.8.3579-3585.2000","article-title":"The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis","volume":"74","author":"Gotte","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2021.03.018_bib0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study","volume":"17","author":"Gregson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0115","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0120","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-saharan african countries: implications for second-line ART strategies","volume":"54","author":"Hamers","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0130","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.ijid.2021.03.018_bib0135","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa","volume":"49","author":"Hoffmann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0140","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jac\/dkaa019","article-title":"M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients","volume":"75","author":"Jary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0150","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021661","article-title":"High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia","volume":"99","author":"Jordan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijid.2021.03.018_bib0155","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/jac\/dkw186","article-title":"Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia","volume":"71","author":"Katlama","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0165","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/jac\/dkx109","article-title":"Dolutegravir monotherapy in HIV-infected naive patients with an HIVRNA load <100 000 copies\/mL: a medium-term follow-up","volume":"72","author":"Lanzafame","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0175","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/00002030-200006160-00017","article-title":"Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine\/lamivudine\/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies","volume":"14","author":"Maguire","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.018_bib0180","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/infdis\/jix015","article-title":"Commonly transmitted HIV-1 drug resistance mutations in reverse-transcriptase and protease in antiretroviral treatment\u2013naive patients and response to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide","volume":"215","author":"Margot","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0185","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00157-17","article-title":"The R263K dolutegravir resistance-associated substitution progressively decreases HIV-1 integration","volume":"8","author":"Mespl\u00e8de","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ijid.2021.03.018_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijid.2021.03.018_bib0195","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3033","article-title":"Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients","volume":"21","author":"Naeger","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2021.03.018_bib0200","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2017.0205","article-title":"Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda","volume":"34","author":"Ndashimye","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijid.2021.03.018_bib0205","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in human immunodeficiency virus treatment-experienced patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0210","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/QAD.0000000000001191","article-title":"The M184I\/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir","volume":"30","author":"Oliveira","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.018_bib0215","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/QAD.0000000000000199","article-title":"Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors","volume":"28","author":"Oliveira","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.018_bib0220","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/JVI.02154-08","article-title":"In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine","volume":"83","author":"Paredes","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2021.03.018_bib0225","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-016-0265-x","article-title":"Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI\/NNRTI resistant viruses","volume":"13","author":"Pham","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijid.2021.03.018_bib0230","series-title":"Successful switch to once-daily single-tablet regimen (STR) containing elvitegravir (EVG) or dolutegravir (DTG) in virologically suppressed HIV-1-infected patients despite archived resistant quasispecies","author":"Pronier","year":"2017"},{"key":"10.1016\/j.ijid.2021.03.018_bib0235","series-title":"Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study","author":"Reynes","year":"2017"},{"key":"10.1016\/j.ijid.2021.03.018_bib0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pone.0145772","article-title":"HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing","volume":"10","author":"Rhee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2021.03.018_bib0245","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0250","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/01.aids.0000131355.44834.e4","article-title":"Phenotypic impact of HIV reverse transcriptase M184I\/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance","volume":"18","author":"Ross","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.018_bib0255","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"S\u00f6rstedt","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2021.03.018_bib0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/hiv.12829","article-title":"Continuation of emtricitabine\/lamivudine within combination antiretroviral therapy following detection of the M184V\/I HIV-1 resistance mutation","volume":"21","author":"Stirrup","year":"2020","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2021.03.018_bib0265","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0270","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.018_bib0275","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0280","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0285","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.03.018_bib0290","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.90.12.5653","article-title":"Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3\u2032-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase","volume":"90","author":"Tisdale","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2021.03.018_bib0295","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/jac\/dkr291","article-title":"Transmission dynamics of the M184V drug resistance mutation in primary HIV infection","volume":"66","author":"Wainberg","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.03.018_bib0300","series-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"WHO","year":"2019"},{"key":"10.1016\/j.ijid.2021.03.018_bib0305","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221002356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221002356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:59:22Z","timestamp":1761119962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221002356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":61,"alternative-id":["S1201971221002356"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.03.018","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dolutegravir response in antiretroviral therapy na\u00efve and experienced patients with M184V\/I: Impact in low-and middle-income settings","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}